The Open Biochemistry Journal

ISSN: 1874-091X ― Volume 14, 2020

In Vitro Analysis of Protein:Protein Interactions in the Human Cancer-Pertinent rp.eL42-p53-Mdm2 Pathway

Blanche Aguida1, 2, Tahar Bouceba3, Jean-Bernard Créchet1, Horrhus Hounguè1, 4, Callinice Capo-Chichi2, Jun-ichi Nakayama5, Soria Baouz1, Hélène Pelczar1, Anne Woisard1, Nathalie Jourdan6, *, Codjo Hountondji1, *
1 Sorbonne Université - Campus Pierre et Marie Curie, Laboratoire SU-UR6 “Enzymology of RNA” (Bât. B); Case Courrier 60 - 4, Place Jussieu, F-75252, Paris Cedex 05, France
2 Laboratory of Biochemistry and Molecular Biology, Institute of Biomedical Sciences, University of Abomey-Calavi, Cotonou, Benin
3 Sorbonne Université - Campus Pierre et Marie Curie, Institut de Biologie Paris Seine (IBPS) Plateforme d’interactions moléculaires, CNRS-FR3631; 7, Quai Saint Bernard, F-75252, Paris Cedex 05, France
4 Laboratory of Medicinal Organic Chemistry (MOCL), Faculty of Health Sciences, 01 BP: 188 Cotonou, Benin
5 Division of Chromatin Regulation, National Institute for Basic Biology, Nishigonaka 38, Myodaiji, Okazaki 444-8585, Japan
6 Sorbonne Université; CNRS Unit Biological Adaptation and Ageing, Photobiology Team, F-75252, Paris Cedex 05, France



We have recently demonstrated that the eukaryote-specific large subunit ribosomal protein (rp) eL42 assists catalysis of peptide bond formation at the peptidyl transferase center of 80S ribosomes in eukaryotic cells. Recently, several ribosomal proteins were shown to have extraribosomal functions independent of protein biosynthesis. Such functions include regulation of apoptosis, cell cycle arrest, cell proliferation, neoplastic transformation, cell migration and invasion, and tumorigenesis through both Mdm2-p53-dependent and p53-independent mechanisms. Our objective is to demonstrate that overexpression of eL42 in tumor may incapacitate cell anti-tumor mechanism through interaction with the tumor suppressor protein p53 and its partner Mdm2.


Co-immunoprecipitation technique and the binding assays on Biacore were used to probe interactions between recombinant eL42, p53 and Mdm2 proteins in a so-called rp-p53-Mdm2 axis.


We demonstrate that the ribosomal protein eL42, the tumor suppressor protein p53 and the ubiquitin E3 ligase Mdm2 interact with each other in a ternary rp.eL42:p53:Mdm2 complex. Precisely, the interaction between eL42 and p53 is characterized by a strong binding affinity (KD value in the nanomolar range) that is likely to trigger the sequestration of p53 and the inhibition of its tumor suppressor activity. Furthermore, the p53:Mdm2 and eL42:Mdm2 complexes exhibit comparable binding affinities in the micromolar range compatible with Mdm2 being the enzyme which ubiquitinates both the p53 and eL42 substrates. Interestingly, pyridoxal 5'-phosphate (PLP), one of the active forms of vitamin B6, binds to eL42 and significantly inhibits the interaction between eL42 and p53, in accordance with the observation that vitamin B6 is associated with reduced risk of cancer.


Our study emphasized one more major mechanism of p53 downregulation involving its sequestration by eL42 upon the overexpression of this ribosomal protein. The mechanism described in the present report complemented the well-known p53 downregulation triggered by proteasomal degradation mediated through its ubiquitination by Mdm2.

Keywords: eL42 protein, Human 80S ribosomes, Tumor suppressor p53, Ubiquitin E3 ligase Mdm2, eL42:p53 and eL42:Mdm2 complexes, Cancer-pertinent rp.eL42-p53-Mdm2 pathway, Binding assays on Biacore, Co-immunoprecipitation.

Article Information

Identifiers and Pagination:

Year: 2019
Volume: 13
First Page: 64
Last Page: 80
Publisher Id: TOBIOCJ-13-64
DOI: 10.2174/1874091X01913010064

Article History:

Received Date: 30/05/2019
Revision Received Date: 15/09/2019
Acceptance Date: 17/09/2019
Electronic publication date: 30/09/2019
Collection year: 2019

© 2019 Aguida et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to these authors at the Sorbonne Université; Campus Pierre et Marie Curie, Laboratoire “Enzymologie de l’ARN”, SU-UR6; Case courrier 60 - 4, Place Jussieu, F-75251, Paris, Cedex 05 France; E-mail:; Sorbonne Université, CNRS Unit Biological Adaptation and Ageing, Photobiology Team, Paris, France; F-75252, Paris Cedex 05, France; E-mail:

Track Your Manuscript:


"We have always had a fruitful cooperation and long-term experience of publishing with Bentham Open."

"A number of our original papers have appeared in its different journals, as the Bentham Open Publishers provides sufficient research in the field of science and technologies (belonging to the pharmaceutical, biotechnology, biomedical industries etc). The staff of the Bentham Open always treat our papers very seriously and gently during the rutile paper reviewing process, so far we always felt their kindness and highly cooperative support. Today, Bentham Open is providing a great support to science and research, giving opportunities of high standard publishing as well as promoting and enhancing selected papers around the world through communication and exchange of global scientific education."

Kholmirzo T. Kholmurodov
Leading Scientist
FLNP (Frank Laboratory of Neutron Physics) JINR (Joint Institute of Nuclear Research) Moscow region, Russia

Browse Contents

Webmaster Contact:
Copyright © 2020 Bentham Open